Arexera Therapeutics plans to launch a Phase 1 trial testing its experimental treatment ATL-101 in Huntington's patients ...

For Jill, the issue isn’t whether life has value. It is what kind of life is being preserved. If she can no longer eat without choking, recognize loved ones, or share what she wants, would inserting a ...

One thing that helps columnist Tanita Allen ease fear about future symptoms is separating what she can do today from what she ...

Columnist Tanita Allen's mindfulness and meditation practice has taught her that she doesn't need to fight herself every ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google My wife, Jill, who is gene-positive with Huntington’s disease (HD ...

Differences in brain connections for people who carry a mutation known to cause Huntington’s disease are detectable decades before the onset of motor symptoms, a study showed. The findings suggested ...

Years ago, my wife, Jill, was at a party talking with a friend. The conversation turned personal, and her friend asked a difficult question. It was the kind of question people sometimes ask when they ...

Apathy, a common symptom of Huntington’s disease, may present even before the development of hallmark motor symptoms and worsens gradually over time, according to a six-year study of people carrying a ...

A novel gene-editing approach that’s designed to alter the huntingtin protein so it’s less prone to forming the toxic clumps that drive Huntington’s disease led to better motor function and less brain ...

Research is currently ongoing to find a cure for Huntington’s disease and to develop new therapies that might be able to prevent or delay disease progression and better manage the symptoms of the ...

A Phase 1 trial will evaluate PTC Therapeutic’s PTC518, its investigational therapy for Huntington’s disease, in healthy volunteers, the company announced. The trial’s first results are expected in ...

Several late-stage clinical trials are now recruiting participants to test whether three experimental oral therapies can slow the progression of Huntington’s disease, with active or planned sites in ...